Literature DB >> 16699001

Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.

Bing Li1, Julie M Decker, Roy W Johnson, Frederic Bibollet-Ruche, Xiping Wei, Joseph Mulenga, Susan Allen, Eric Hunter, Beatrice H Hahn, George M Shaw, Jerry L Blackwell, Cynthia A Derdeyn.   

Abstract

Information about neutralizing antibody responses in subtype C-infected individuals is limited, even though this viral subtype causes the majority of AIDS cases worldwide. Here we compared the course and magnitude of the autologous neutralizing antibody (NAb) response against viral envelope (Env) glycoproteins present during acute and early infection with subtypes B and C human immunodeficiency virus type 1 (HIV-1). NAb responses were evaluated in 6 subtype B-infected and 11 subtype C-infected subjects over a mean evaluation period of 25 months using a pseudovirus reporter gene assay. All subjects in the C cohort were infected through heterosexual contact, while five of the six subjects in the B cohort were infected via male-to-male contact. The kinetics and magnitude of the NAb responses varied among subjects in the B and C cohorts; however, the median 50% inhibitory concentration (IC(50) titer) reached by antibody in the plasma of subtype C-infected subjects, overall, was 3.5-fold higher than in the subtype B-infected subjects (P = 0.06). The higher titers of NAbs in the C cohort were associated with viruses having significantly shorter amino acid length (P = 0.002) in the V1 to V4 region of the surface Env glycoprotein, gp120, compared to the B cohort. Despite the potency of the autologous subtype C NAb response, it was not directed against cross-neutralizing epitopes. These data demonstrate that subtype C Envs elicit a potent yet restricted NAb response early in infection that frequently reaches IC(50) titers in excess of 1:1,000 and suggest that clade-specific differences may exist in Env immunogenicity or susceptibility to neutralization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699001      PMCID: PMC1472127          DOI: 10.1128/JVI.00201-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.

Authors:  Cynthia A Derdeyn; Julie M Decker; Frederic Bibollet-Ruche; John L Mokili; Mark Muldoon; Scott A Denham; Marintha L Heil; Francis Kasolo; Rosemary Musonda; Beatrice H Hahn; George M Shaw; Bette T Korber; Susan Allen; Eric Hunter
Journal:  Science       Date:  2004-03-26       Impact factor: 47.728

2.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

Authors:  G J LaRosa; J P Davide; K Weinhold; J A Waterbury; A T Profy; J A Lewis; A J Langlois; G R Dreesman; R N Boswell; P Shadduck
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

4.  Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors.

Authors:  A P Bradney; S Scheer; J M Crawford; S P Buchbinder; D C Montefiori
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

5.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

Review 6.  Immunodeficiency virus exploitation of dendritic cells in the early steps of infection.

Authors:  Natalia Teleshova; Ines Frank; Melissa Pope
Journal:  J Leukoc Biol       Date:  2003-07-22       Impact factor: 4.962

Review 7.  Macrophage HIV-1 infection and the gastrointestinal tract reservoir.

Authors:  Phillip D Smith; Gang Meng; Jesus F Salazar-Gonzalez; George M Shaw
Journal:  J Leukoc Biol       Date:  2003-08-11       Impact factor: 4.962

8.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

Authors:  J Albert; B Abrahamsson; K Nagy; E Aurelius; H Gaines; G Nyström; E M Fenyö
Journal:  AIDS       Date:  1990-02       Impact factor: 4.177

9.  Chemokine receptor expression on mucosal dendritic cells from the endocervix of healthy women.

Authors:  Manyu Prakash; Moses S Kapembwa; Frances Gotch; Steve Patterson
Journal:  J Infect Dis       Date:  2004-06-18       Impact factor: 5.226

10.  Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies.

Authors:  M Arendrup; C Nielsen; J E Hansen; C Pedersen; L Mathiesen; J O Nielsen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992
View more
  106 in total

1.  The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.

Authors:  Rebecca M Lynch; Rong Rong; Saikat Boliar; Anurag Sethi; Bing Li; Joseph Mulenga; Susan Allen; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

2.  Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

Authors:  L Diomede; S Nyoka; C Pastori; L Scotti; A Zambon; G Sherman; C M Gray; M Sarzotti-Kelsoe; L Lopalco
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

3.  Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.

Authors:  Ming Li; Jesus F Salazar-Gonzalez; Cynthia A Derdeyn; Lynn Morris; Carolyn Williamson; James E Robinson; Julie M Decker; Yingying Li; Maria G Salazar; Victoria R Polonis; Koleka Mlisana; Salim Abdool Karim; Kunxue Hong; Kelli M Greene; Miroslawa Bilska; Jintao Zhou; Susan Allen; Elwyn Chomba; Joseph Mulenga; Cheswa Vwalika; Feng Gao; Ming Zhang; Bette T M Korber; Eric Hunter; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

4.  Depletion of CD4⁺ T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques.

Authors:  Alexandra M Ortiz; Nichole R Klatt; Bing Li; Yanjie Yi; Brian Tabb; Xing Pei Hao; Lawrence Sternberg; Benton Lawson; Paul M Carnathan; Elizabeth M Cramer; Jessica C Engram; Dawn M Little; Elena Ryzhova; Francisco Gonzalez-Scarano; Mirko Paiardini; Aftab A Ansari; Sarah Ratcliffe; James G Else; Jason M Brenchley; Ronald G Collman; Jacob D Estes; Cynthia A Derdeyn; Guido Silvestri
Journal:  J Clin Invest       Date:  2011-10-17       Impact factor: 14.808

5.  Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.

Authors:  Evelien M Bunnik; Esther D Quakkelaar; Ad C van Nuenen; Brigitte Boeser-Nunnink; Hanneke Schuitemaker
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Authors:  Rong Rong; Frederic Bibollet-Ruche; Joseph Mulenga; Susan Allen; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Elias Woldegabriel; Lemme Kebaabetswe; Raabya Rossenkhan; Busisiwe Mlotshwa; Caitlin Bonney; Mariel Finucane; Rosemary Musonda; Sikhulile Moyo; Carolyn Wester; Erik van Widenfelt; Joseph Makhema; Stephen Lagakos; M Essex
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

8.  High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Authors:  Katie L Davis; Elin S Gray; Penny L Moore; Julie M Decker; Aidy Salomon; David C Montefiori; Barney S Graham; Michael C Keefer; Abraham Pinter; Lynn Morris; Beatrice H Hahn; George M Shaw
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

9.  Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.

Authors:  Catherine A Blish; D Noah Sather; George Sellhorn; Leonidas Stamatatos; Yide Sun; Indresh Srivastava; Susan W Barnett; Brad Cleveland; Julie Overbaugh; Shiu-lok Hu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

10.  Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India.

Authors:  Smita Kulkarni; Srikanth Tripathy; Raman Gangakhedkar; Sushama Jadhav; Kalpana Agnihotri; Suvarna Sane; Robert Bollinger; Ramesh Paranjape
Journal:  AIDS Res Hum Retroviruses       Date:  2008-09       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.